Clinical Trials Browser

Phase 1/2 × Neoplasms × SNX-5422 × Clear all

NCT01848756 2017-02-09

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

Phase 1/2 Terminated

15 enrolled 10 charts

Neoplasms